“The greatest need we have today in the human cancer problem, except for a universal cure, is a method for detecting cancer before there are any clinical signs or symptoms.”
Sidney Farber, M.D.
Father of modern chemotherapy
pioneering the detection of early cancer
Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. Incubated within Flagship Pioneering for three years before launching in 2021, Harbinger combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test.
A harbinger is a “forerunner, that which precedes and gives notice of the coming of another.” We not only are working to identify the harbinger – the biological programs present in the earliest forms of cancer – but seek to be the harbinger, to be the forerunner which will usher in the future of healthcare.
At Harbinger, we intend to lead in shaping this future – creating a proactive paradigm so that people can live cancer-free for longer, adding years to life and life to years. We envision a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies.
Our answer to the problem of late cancer detection and unacceptable patient prognoses starts with our proprietary solutions for the future of cancer pre-emption. Beginning with blood-based tests, we will enable cancer detection before it is visible. By identifying biological programs rooted in cancer's origins, we can enable identification of early stage and pre-disease. Through this new pathway for cancer diagnosis and early therapeutic interventions, Harbinger Health has the potential to fundamentally change cancer care, for everyone.
Dave joined Harbinger Health in early 2023 and serves as SVP, Portfolio Strategy and Operations.
Dave brings over 20 years of experience working in pharma and biotech with various roles in Finance, Portfolio, Strategy and Operations. Immediately prior to joining Harbinger Health, Dave worked for Alexion Pharmaceuticals for 6 years until it was acquired by AstraZeneca in 2021 and spent another 2 years post-acquisition in the Alexion Business Unit. His most recent role at Alexion was Executive Director, Business Operations supporting the office of the CEO. In addition to this role, during his time at Alexion he held various positions within the R&D Portfolio Operations team and served as Chief of Staff to the Head of R&D. Prior to Alexion, Dave spent 15 years at Pfizer where he held a number of positions within the R&D Finance team managing annual budgets of in excess of $1b+ before joining the R&D Portfolio Operations team where responsibilities included goal setting, resource allocation, budgeting, operations and reporting.
Dave holds degrees in Business Management & Finance from Providence College and obtained his MBA from the University of Connecticut.
our leadership team
our board of directors
Director, Social & Behavioral Sciences, Community Engagement
Operation Warp Speed
Professor, Department of Gastrointestical Medical Oncology
Chair Department of Investigational Cancer Therapeutics
Chief Quality Officer
Board member, Kaiser Foundation